Loading organizations...
§ Private Profile · Framingham, MA, USA
Clinical-stage biopharmaceutical company develops oral treatments for Alzheimer's and neurodegenerative disorders, blocking toxic amyloid oligomers.
Founded in 2013 by Martin Tolar, Alzheon is a clinical-stage biopharmaceutical company based in Framingham, Massachusetts, developing targeted oral treatments for Alzheimer’s disease and other neurodegenerative disorders. The enterprise primarily focuses on advancing its lead drug candidate, ALZ-801, which is designed to block the formation of neurotoxic amyloid oligomers in high-risk patients to prevent cognitive decline. Operating with an estimated workforce of 10 to 50 employees, the firm has secured more than $100 million in total financing to support its late-stage clinical trials. This capital includes a $50 million Series E funding round led by Ally Bridge Group, alongside a $47 million research grant awarded by the National Institute on Aging. Guided by executives like Chief Scientific Officer John Hey, the organization recently completed its APOLLOE4 Phase 3 clinical trial evaluating ALZ-801 in patients with early Alzheimer's disease.
Alzheon has raised $160.0M across 3 funding rounds.
Alzheon has raised $160.0M in total across 3 funding rounds.
Alzheon has raised $160.0M in total across 3 funding rounds.
Alzheon's investors include Alerce Medical Technology Partners, Ally Bridge Group.
Alzheon has raised $160.0M across 3 funding rounds. Most recently, it raised $100.0M Series E in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 12, 2024 | $100M Series E | Alerce Medical Technology Partners | — | Announced |
| Apr 14, 2022 | $50M Series D | — | — | Announced |
| Apr 8, 2015 | $10M Series A | Ally Bridge Group | — | Announced |